ARVINAS, INC.

Based in New Haven, Connecticut, Arvinas is a clinical-stage biotechnology company focused on developing targeted protein degradation therapies. The company's platform centers on proteolysis targeting chimeras (PROTACs), a drug modality designed to harness the body's natural protein disposal mechanisms to degrade disease-causing proteins. This approach differs from traditional therapeutics that typically inhibit protein function rather than eliminate the proteins entirely.

Arvinas maintains a pipeline spanning multiple therapeutic areas. In oncology, the company is advancing ARV-806 for KRAS G12D-mutant cancers, ARV-393 for relapsed/refractory non-Hodgkin lymphoma, and two orally bioavailable PROTAC degraders—Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766)—for metastatic castration-resistant prostate cancer. In neurology, ARV-102 targets LRRK2 for Parkinson's disease and progressive supranuclear palsy. ARV-027 is in development for polyglutamine-expanded androgen receptor disorders, while vepdegestrant targets estrogen receptor in ER+/HER2- breast cancer.

The company operates partnerships with major pharmaceutical firms including Pfizer, Roche, Genentech, and Bayer, which provide both development funding and commercialization support. Founded in 2013, Arvinas operates primarily from its Connecticut headquarters. As a clinical-stage company without significant commercial revenue, the organization remains dependent on collaboration agreements and capital resources to fund its development programs.